Nature Commun:微型眼贴可递送药物至眼球

2018-11-09 晋楠 中国科学报

一篇新论文介绍了一种可以将药物递送至眼睛治疗疾病的微型眼贴。该装置已在小鼠身上进行了测试,有望使患者在家中完成眼部疾病自我治疗。


一篇新论文介绍了一种可以将药物递送至眼睛治疗疾病的微型眼贴。该装置已在小鼠身上进行了测试,有望使患者在家中完成眼部疾病自我治疗。

在治疗威胁视力的疾病(如青光眼和年龄相关性黄斑变性)时,许多药物直接入眼是最安全和最有效的。但注射可能引起不适、感染和严重眼损伤等问题,滴眼液则可能被洗掉且通常效率低下。

新加坡南洋理工大学的陈鹏及同事开发了一种毫米大小的眼贴,上面包含微针阵列,这些微针以有控制的方式将药物递送至眼球。微针会逐渐溶解,缓慢地将药物释放到周围环境中。相关成果近日在线发表于《自然—通讯》。

在小鼠实验中,研究人员用拇指短暂轻压,将上述眼贴贴在小鼠眼表面。研究者使用角膜新生血管作为模型,证明利用眼贴递送单克隆抗体DC101进行单次治疗后,小鼠的新生血管面积减小了约90%。相比之下,即使使用更高剂量的滴眼液,也无法取得显著的治疗效果。未来还需要开展临床研究评估这种新装置对人类的有效性和安全性。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1883413, encodeId=d9d5188341388, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Feb 25 02:57:00 CST 2019, time=2019-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087455, encodeId=a42c208e4556e, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue Jun 18 15:57:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1684058, encodeId=8c1f1684058ec, content=<a href='/topic/show?id=a9fee2770d0' target=_blank style='color:#2F92EE;'>#眼球#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72770, encryptionId=a9fee2770d0, topicName=眼球)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a38928025675, createdName=刘阔, createdTime=Tue Nov 20 19:57:00 CST 2018, time=2018-11-20, status=1, ipAttribution=)]
    2019-02-25 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1883413, encodeId=d9d5188341388, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Feb 25 02:57:00 CST 2019, time=2019-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087455, encodeId=a42c208e4556e, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue Jun 18 15:57:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1684058, encodeId=8c1f1684058ec, content=<a href='/topic/show?id=a9fee2770d0' target=_blank style='color:#2F92EE;'>#眼球#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72770, encryptionId=a9fee2770d0, topicName=眼球)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a38928025675, createdName=刘阔, createdTime=Tue Nov 20 19:57:00 CST 2018, time=2018-11-20, status=1, ipAttribution=)]
    2019-06-18 liuli5079
  3. [GetPortalCommentsPageByObjectIdResponse(id=1883413, encodeId=d9d5188341388, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Feb 25 02:57:00 CST 2019, time=2019-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087455, encodeId=a42c208e4556e, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue Jun 18 15:57:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1684058, encodeId=8c1f1684058ec, content=<a href='/topic/show?id=a9fee2770d0' target=_blank style='color:#2F92EE;'>#眼球#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72770, encryptionId=a9fee2770d0, topicName=眼球)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a38928025675, createdName=刘阔, createdTime=Tue Nov 20 19:57:00 CST 2018, time=2018-11-20, status=1, ipAttribution=)]
    2018-11-20 刘阔